Close Menu

NEW YORK – Rebus Biosystems, most recently known as Optical Biosystems, announced Thursday it has closed a $20 million Series B financing round, led by Illumina Ventures.

Lifecore Partners, Ncore Ventures, Xolon Invest, CTK Investments, Ray, Seegene Medical Foundation, LabGenomics, and Timefolio Asset Management joined the round.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.